Suppr超能文献

淋病奈瑟菌所致尿道感染的实验研究。

Experimental Urethral Infection with Neisseria gonorrhoeae.

机构信息

School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, USA.

Brigham and Women's Hospital, Harvard Medical School, Boston, USA.

出版信息

Curr Top Microbiol Immunol. 2024;445:109-125. doi: 10.1007/82_2021_250.

Abstract

Gonorrhea rates and antibiotic resistance are both increasing. Neisseria gonorrhoeae (Ng) is an exclusively human pathogen and is exquisitely adapted to its natural host. Ng can subvert immune responses and undergoes frequent antigenic variation, resulting in limited immunity and protection from reinfection. Previous gonococcal vaccine efforts have been largely unsuccessful, and the last vaccine to be tested in humans was more than 35 years ago. Advancing technologies and the threat of untreatable gonorrhea have fueled renewed pursuit of a vaccine as a long-term sustainable solution for gonorrhea control. Despite the development of a female mouse model of genital gonococcal infection two decades ago, correlates of immunity or protection remain largely unknown, making the gonococcus a challenging vaccine target. The controlled human urethral infection model of gonorrhea (Ng CHIM) has been used to study gonococcal pathogenesis and the basis of anti-gonococcal immunity. Over 200 participants have been inoculated without serious adverse events. The Ng CHIM replicates the early natural course of urethral infection. We are now at an inflexion point to pivot the use of the model for vaccine testing to address the urgency of improved gonorrhea control. Herein we discuss the need for gonorrhea vaccines, and the advantages and limitations of the Ng CHIM in accelerating the development of gonorrhea vaccines.

摘要

淋病发病率和抗生素耐药率均呈上升趋势。淋病奈瑟菌(Ng)是一种专性人类病原体,对其自然宿主具有高度适应性。Ng 可以颠覆免疫反应,并经历频繁的抗原变异,导致有限的免疫力和防止再次感染的保护。以前的淋病疫苗研究工作大多没有成功,最后一次在人类身上测试的疫苗是在 35 年多前。先进的技术和无法治疗的淋病的威胁,促使人们重新寻求疫苗作为淋病控制的长期可持续解决方案。尽管二十年前已经开发出了一种用于研究生殖道淋病感染的雌性小鼠模型,但对免疫或保护的相关性仍知之甚少,这使得淋球菌成为一个具有挑战性的疫苗靶标。淋病奈瑟菌控制的人体尿道感染模型(Ng CHIM)已被用于研究淋病奈瑟菌的发病机制和抗淋病奈瑟菌免疫的基础。已有超过 200 名参与者接种了该模型,没有发生严重的不良事件。Ng CHIM 复制了尿道感染的早期自然病程。我们现在正处于一个转折点,即将该模型用于疫苗测试,以应对改善淋病控制的紧迫性。本文讨论了淋病疫苗的必要性,以及 Ng CHIM 在加速淋病疫苗开发方面的优势和局限性。

相似文献

1
Experimental Urethral Infection with Neisseria gonorrhoeae.
Curr Top Microbiol Immunol. 2024;445:109-125. doi: 10.1007/82_2021_250.
2
Progress Toward a Gonococcal Vaccine: The Way Forward.
Front Immunol. 2019 Oct 15;10:2417. doi: 10.3389/fimmu.2019.02417. eCollection 2019.
3
Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development.
Crit Rev Microbiol. 2016 Nov;42(6):928-41. doi: 10.3109/1040841X.2015.1105782. Epub 2016 Jan 23.
4
Immune responses to and implications for vaccine development.
Front Immunol. 2023 Aug 17;14:1248613. doi: 10.3389/fimmu.2023.1248613. eCollection 2023.
5
Neisseria gonorrhoeae: Drug Resistance, Mouse Models, and Vaccine Development.
Annu Rev Microbiol. 2017 Sep 8;71:665-686. doi: 10.1146/annurev-micro-090816-093530.
6
Female Mouse Model of Neisseria gonorrhoeae Infection.
Methods Mol Biol. 2019;1997:413-429. doi: 10.1007/978-1-4939-9496-0_24.
7
The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.
PLoS Pathog. 2020 Dec 8;16(12):e1008602. doi: 10.1371/journal.ppat.1008602. eCollection 2020 Dec.
8
Biology of the Gonococcus: Disease and Pathogenesis.
Methods Mol Biol. 2019;1997:1-27. doi: 10.1007/978-1-4939-9496-0_1.
10
Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine.
mBio. 2019 Nov 5;10(6):e02552-19. doi: 10.1128/mBio.02552-19.

引用本文的文献

2
vaccines: a contemporary overview.
Clin Microbiol Rev. 2024 Mar 14;37(1):e0009423. doi: 10.1128/cmr.00094-23. Epub 2024 Jan 16.
3
Vaccine value profile for Neisseria gonorrhoeae.
Vaccine. 2024 Jul 25;42(19S1):S42-S69. doi: 10.1016/j.vaccine.2023.01.053. Epub 2023 Dec 13.
4
Promising developments in gonococcal vaccines.
Curr Opin Infect Dis. 2024 Feb 1;37(1):63-69. doi: 10.1097/QCO.0000000000000992. Epub 2023 Dec 4.
5
Comparison of lipooligosaccharides from human challenge strains of .
Front Microbiol. 2023 Sep 15;14:1215946. doi: 10.3389/fmicb.2023.1215946. eCollection 2023.
7
Vertebrate and Invertebrate Animal and New In Vitro Models for Studying Biology.
Pathogens. 2023 May 30;12(6):782. doi: 10.3390/pathogens12060782.

本文引用的文献

1
Nonviral sexually transmitted infections in pregnancy: current controversies and new challenges.
Curr Opin Infect Dis. 2021 Feb 1;34(1):40-49. doi: 10.1097/QCO.0000000000000702.
2
Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020.
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1911-1916. doi: 10.15585/mmwr.mm6950a6.
3
The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.
PLoS Pathog. 2020 Dec 8;16(12):e1008602. doi: 10.1371/journal.ppat.1008602. eCollection 2020 Dec.
5
Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine.
mBio. 2019 Nov 5;10(6):e02552-19. doi: 10.1128/mBio.02552-19.
8
Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016.
Bull World Health Organ. 2019 Aug 1;97(8):548-562P. doi: 10.2471/BLT.18.228486. Epub 2019 Jun 6.
9
Female Mouse Model of Neisseria gonorrhoeae Infection.
Methods Mol Biol. 2019;1997:413-429. doi: 10.1007/978-1-4939-9496-0_24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验